Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 5.7% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc 5.7% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ this morning by analysts at JP Morgan Cazenove. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set a target price of 1800 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 5.7% from the opening price of 1702.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 67 points and decreased 212 points respectively. The 1 year high for the share price is 2089 GBX while the year low stock price is currently 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,822.02 GBX and a 200 day moving average of 1,646.87. There are currently 241,455,394 shares in issue with the average daily volume traded being 742,063. Market capitalisation for LON:HIK is £4,138,545,453 GBP.